Cheryl Pegus

Board Director

Director

Phreesia, Inc.Concentra Group Holdings Parent, Inc.Boston Scientific Corp

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 1 buy · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€86k

▼ Sales (0 ops.)

—

Latest filing published 21 May 2026 for Boston Scientific CORP, €86k. Read the official filing

Filing timeline

BuySale

Cheryl Pegus

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Cheryl Pegus: trading record in brief

This profile gathers the share dealings of Cheryl Pegus across 3 companies, led by Concentra Group Holdings Parent, Inc., Phreesia, Inc. and Boston Scientific Corp. Over a trading history stretching from 24 May 2021 to 20 May 2026, the count stands at 5 filings.

Purchases make up the whole of the open-market record (1 purchase, €86k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 4 share grants. So far in 2026, the count stands at 1 purchase and no sales.

Most recently, on 21 May 2026, the filings show an open-market purchase worth €86k in Boston Scientific Corp. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.